Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1133-1139

  Jia, Hu Liang ^a,c   Ye, Qing Hai ^c   Qin, Lun Xiu ^c   Budhu, Anuradha ^a   Forgues, Marshonna ^a   Chen, Yidong ^b   Liu, Yin Kun ^c   Sun, Hui Chuan ^c   Wang, Lu ^c   Lu, Hong Zhou ^d   Shen, Fang ^d   Tang, Zhao You ^c   Xin, Wei Wang ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c FUDAN UNIVERSITY   (China)

^d Shanghai Public Health Clinical Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GLYCOPROTEIN; GLYPICAN 3; PROTEIN DERIVATIVE; PROTEIN MDK; PROTEIN PEG10; PROTEIN SERPINI1; TUMOR PROTEIN; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA FINGERPRINTING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GLYPICANS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NEUROPEPTIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTEINS; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947204625     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1025     Document Type: Article

References (29)

1. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997;350:1142-3.
2. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998;351:214-5.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
4. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
5. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005;14:243-50.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
7. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5.
8. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001;91:1479-86.
9. Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34:707-13.
10. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-82.
11. Johnson PJ. The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.
12. Nakakura EK, Choti MA. Management of hepatocellularcarcinoma. Oncology (Huntingt) 2000;14:1085-98.
13. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
14. Taketa K. α-Fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420-32.
15. Kim JW, Ye Q, Forgues M, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004;39:518-27.
16. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23.
17. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of α-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003;23:1747-53.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
19. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
20. Ikematsu S, Yano A, Aridome K, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 2000;83:701-6.
21. Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med 2000;124:848-52.
22. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995;221:291-8.
23. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77.
24. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
25. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
26. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-8.
27. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988;151:1312-8.
28. Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T. Midkine, a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution. Dev Biol 1993;159:392-402.
29. Tsou AP, Chuang YC, Su JY, et al. Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. J Biomed Sci 2003;10:625-35.